These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 39071617)

  • 1. Deep learning for predicting fibrotic progression risk in diabetic individuals with metabolic dysfunction-associated steatotic liver disease initially free of hepatic fibrosis.
    Dai R; Sun M; Lu M; Deng L
    Heliyon; 2024 Jul; 10(13):e34150. PubMed ID: 39071617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Interpretable Machine Learning Models Based on Ultrasonic Radiomics for Predicting the Risk of Fibrosis Progression in Diabetic Patients with Nonalcoholic Fatty Liver Disease.
    Meng F; Wu Q; Zhang W; Hou S
    Diabetes Metab Syndr Obes; 2023; 16():3901-3913. PubMed ID: 38077485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis of steatohepatitis and fibrosis in biopsy-proven nonalcoholic fatty liver diseases: including two-dimension real-time shear wave elastography and noninvasive fibrotic biomarker scores.
    Zhou J; Yan F; Xu J; Lu Q; Zhu X; Gao B; Zhang H; Yang R; Luo Y
    Quant Imaging Med Surg; 2022 Mar; 12(3):1800-1814. PubMed ID: 35284290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing Liver Fibrosis in Type 2 Diabetes Mellitus Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: The Role of Non-invasive Scoring Systems and Associated Factors.
    Naskar A; Mondal A; Chatterjee R; De RD; Roy S
    Cureus; 2024 Jun; 16(6):e62405. PubMed ID: 39011198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasound Shear Wave Elastography for Liver Disease. A Critical Appraisal of the Many Actors on the Stage.
    Piscaglia F; Salvatore V; Mulazzani L; Cantisani V; Schiavone C
    Ultraschall Med; 2016 Feb; 37(1):1-5. PubMed ID: 26871407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The deep abdominal ultrasound transducer (DAX) increases the success rate and diagnostic accuracy of shear wave elastography for liver fibrosis assessment in patients with obesity-A prospective biopsy-controlled study.
    Bauer DJM; Nixdorf L; Dominik N; Schwarz M; Hofer BS; Hartl L; Semmler G; Jachs M; Simbrunner B; Jedamzik J; Mozayani B; Gensthaler L; Felsenreich DM; Trauner M; Langer FB; Mandorfer M; Prager G; Reiberger T
    Aliment Pharmacol Ther; 2024 Jul; 60(1):70-82. PubMed ID: 38693718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.
    Con D; Tu S; Clayton-Chubb D; Lubel JS; Nicoll AJ; Sawhney R; Bloom S
    Dig Dis Sci; 2024 Apr; 69(4):1496-1506. PubMed ID: 38376788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe hepatic steatosis promotes increased liver stiffness in the early stages of metabolic dysfunction-associated steatotic liver disease.
    Kumada T; Toyoda H; Ogawa S; Gotoh T; Suzuki Y; Sugimoto K; Yoshida Y; Kuroda H; Kamada Y; Sumida Y; Ito T; Akita T; Tanaka J
    Liver Int; 2024 Jul; 44(7):1700-1714. PubMed ID: 38558221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Portal Venous Pulsatility Index and Main Portal Vein Diameter as Surrogate Markers for Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Metabolic-Dysfunction-Associated Steatotic Liver Disease.
    Lee J; Choi S; Cho SH; Yang H; Sung PS; Bae SH
    Diagnostics (Basel); 2024 Feb; 14(4):. PubMed ID: 38396432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
    Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
    Eur Radiol; 2024 Jun; 34(6):3882-3888. PubMed ID: 37987833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific metabolic impairments indicate loss of sustained liver improvements in metabolic dysfunction-associated steatotic liver disease treatment.
    Luo L; Ye J; Zhuo S; Ma B; Mai W; Cao X; Liang L; Wang W; Feng S; Dong Z; Zhong B
    Hepatobiliary Surg Nutr; 2024 Aug; 13(4):632-649. PubMed ID: 39175719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performances of Fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction-associated steatotic liver disease in Asian primary care clinics.
    Park H; Kim M; Kim HL; Cho S; Yoon EL; Jun DW
    Hepatol Res; 2024 Nov; 54(11):1027-1034. PubMed ID: 38703383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography.
    Kobayashi T; Iwaki M; Nogami A; Kawamura N; Honda Y; Ogawa Y; Imajo K; Yoneda M; Saito S; Nakajima A
    J Gastroenterol; 2024 Jan; 59(1):56-65. PubMed ID: 37845417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine-learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD-related liver fibrosis.
    Fan R; Yu N; Li G; Arshad T; Liu WY; Wong GL; Liang X; Chen Y; Jin XZ; Leung HH; Chen J; Wang XD; Yip TC; Sanyal AJ; Sun J; Wong VW; Zheng MH; Hou J
    Liver Int; 2024 Mar; 44(3):749-759. PubMed ID: 38131420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of novel collagen turnover biomarkers to detect increased liver stiffness in MASLD.
    Hegmar H; Wiggers T; Nasr P; Vessby J; Kechagias S; Nyhlin N; Marschall HU; Borssén ÅD; Strandberg R; Karsdal M; Leeming DJ; Ekstedt M; Hagström H
    J Intern Med; 2024 Aug; 296(2):177-186. PubMed ID: 38959258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic performance of two-dimensional shear wave elastography and attenuation imaging for fibrosis and steatosis assessment in chronic liver disease.
    Kobayashi T; Nakatsuka T; Sato M; Soroida Y; Hikita H; Gotoh H; Iwai T; Tateishi R; Kurano M; Fujishiro M
    J Med Ultrason (2001); 2024 Jun; ():. PubMed ID: 38951430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The associations between fibrosis changes and liver-related events in patients with metabolic dysfunction-associated steatotic liver disease.
    Lee HW; Kim KH; Ahn SH; Lee HC; Choi J
    Liver Int; 2024 Jun; 44(6):1448-1455. PubMed ID: 38488679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies.
    Forlano R; Stanic T; Jayawardana S; Mullish BH; Yee M; Mossialos E; Goldin R; Petta S; Tsochatzis E; Thursz M; Manousou P
    Liver Int; 2024 Jan; 44(1):61-71. PubMed ID: 37718933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.